Log in
NASDAQ:EQ

Equillium Stock Forecast, Price & News

$4.90
-0.03 (-0.61 %)
(As of 12/4/2020 12:00 AM ET)
Add
Compare
Today's Range
$4.80
Now: $4.90
$5.13
50-Day Range
$3.48
MA: $5.16
$6.35
52-Week Range
$2.20
Now: $4.90
$27.05
Volume430,244 shs
Average Volume1.13 million shs
Market Capitalization$121.17 million
P/E RatioN/A
Dividend YieldN/A
Beta2.19
Equillium, Inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was founded in 2017 and is headquartered in La Jolla, California.

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.99 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone858 412 5302
Employees22

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.16 per share

Profitability

Net Income$-25,600,000.00

Miscellaneous

Market Cap$121.17 million
Next Earnings Date3/25/2021 (Estimated)
OptionableNot Optionable
$4.90
-0.03 (-0.61 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EQ News and Ratings via Email

Sign-up to receive the latest news and ratings for EQ and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Equillium (NASDAQ:EQ) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Equillium?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Equillium in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Equillium
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Equillium?

Wall Street analysts have given Equillium a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Equillium wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Equillium's next earnings date?

Equillium is scheduled to release its next quarterly earnings announcement on Thursday, March 25th 2021.
View our earnings forecast for Equillium
.

How were Equillium's earnings last quarter?

Equillium, Inc. (NASDAQ:EQ) released its earnings results on Tuesday, November, 10th. The company reported ($0.31) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.41) by $0.10.
View Equillium's earnings history
.

What price target have analysts set for EQ?

1 brokers have issued 1 year price targets for Equillium's shares. Their forecasts range from $12.00 to $12.00. On average, they expect Equillium's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 144.9% from the stock's current price.
View analysts' price targets for Equillium
.

Who are some of Equillium's key competitors?

Who are Equillium's key executives?

Equillium's management team includes the following people:
  • Mr. Daniel Mark Bradbury, Exec. Chairman (Age 59, Pay $578k)
  • Mr. Bruce D. Steel C.F.A., Co-Founder, Pres, CEO & Director (Age 54, Pay $538.33k)
  • Dr. Krishna R. Polu, Exec. VP of R&D and Chief Medical Officer (Age 47, Pay $556.75k)
  • Mr. Jason A. Keyes, Chief Financial Officer (Age 49)
  • Ms. Christine Zedelmayer M.B.A., P.M.P., Sr. VP & COO (Age 50)
  • Dr. Stephen Connelly Ph.D., Chief Scientific Officer & Director (Age 38)
  • Matthew Ritter Ph.D., VP of Corp. Devel.
  • Mr. Joel M. Rothman, Sr. VP of Devel. Operations

When did Equillium IPO?

(EQ) raised $70 million in an IPO on Friday, October 12th 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and Stifel served as the underwriters for the IPO.

What is Equillium's stock symbol?

Equillium trades on the NASDAQ under the ticker symbol "EQ."

How do I buy shares of Equillium?

Shares of EQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Equillium's stock price today?

One share of EQ stock can currently be purchased for approximately $4.90.

How big of a company is Equillium?

Equillium has a market capitalization of $121.17 million. The company earns $-25,600,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis. Equillium employs 22 workers across the globe.

What is Equillium's official website?

The official website for Equillium is equilliumbio.com.

How can I contact Equillium?

Equillium's mailing address is 2223 AVENIDA DE LA PLAYA SUITE 108, LA JOLLA CA, 92037. The company can be reached via phone at 858 412 5302 or via email at [email protected]

This page was last updated on 12/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.